Lexaria raises about $5.9 million through warrant exercise inducement deal
Holders agreed to immediately exercise existing warrants at a reduced price, with H.C. Wainwright acting as placement agent for the September 9, 2026 closing.
Lexaria Bioscience Corp. announced on September 8, 2026 that it entered into inducement offer letter agreements dated September 7, 2026 with holders of existing warrants to purchase up to an aggregate of 453,969 shares of common stock. The existing warrants were originally issued on February 16, 2024 at $32.78 per share, October 16, 2024 at $45.90 per share, September 29, 2025 at $20.55 per share, and December 16, 2025 at $17.85 per share, and holders agreed to immediately exercise them at a reduced price of $12.92 per share.1
Gross proceeds to the company from the exercise were approximately $5.9 million, before placement agent fees and offering expenses.1
In exchange, Lexaria agreed to issue new unregistered Series A warrants for up to 453,969 shares at $12.67 per share, exercisable immediately with a five-year term, along with short-term Series B warrants at the same $12.67 exercise price and immediately exercisable but expiring after eighteen months.1
H.C. Wainwright & Co., LLC served as exclusive placement agent, earning a fee equal to 7% of gross proceeds, and also received placement agent warrants to purchase 15,889 shares at $16.15 per share.1
Closing of the transactions was expected on September 9, 2026, subject to customary closing conditions.1 The company said it plans to use net proceeds for working capital and general corporate purposes.1
Lexaria also agreed to file a resale registration statement for shares underlying the new warrants within thirty days of the inducement letters, and to seek SEC effectiveness within forty-five days, or sixty days if subject to a full review.1
CEO Rich Christopher said in the release, "We are extremely pleased for the potential $5.9 million in gross cash proceeds from the exercise of warrants," and added that combined with a $2.6 million tax rebate the company said it recently received from the Australian Tax Office, the funds may be utilized to fund operations and research and development programs in 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.